GI
Insider
Gilead Sciences, Inc.
10% ownerGilead Sciences, Inc. (10% owner) filed 4 Form 4 reports as a reporting entity in the past 24 months (4 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in Assembly Biosciences, Inc. (ASMB). Across 4 priced purchase filings, the average 21-session return was +4.2% from execution and +0.5% from disclosure (delay-adjusted; derived). The largest single filing was $55.0M of ASMB (as filed), executed Aug 8 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+4.2%
avg across 4 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+0.5%
same 4 filings, from disclosure
Filings, ttm
4
4 buys · 0 sells · 1 late
Median delay
3d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$92.0M
shares × price, as filed
Last traded
Aug 8 2025
Filed Oct 3 2025
Median ADV $5.8M across their filed names
Open performance→Volume by month
Buys $92.0M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Not on file
1 filing
Sector per market data · by filing · past 24 months
Most traded names
ASMBRecent filings
ASMBPURCHASE
Assembly Biosciences, Inc.
View filing →
$55.0Mas filed
Exec Aug 8 2025
Filed Oct 3 2025 · 4:30 PM ET † RCUSPURCHASE Arcus Biosciences, Inc. View filing → $15.0M
1,363,636 sh × $11.00
Exec Feb 18 2025
Filed Feb 20 2025 · 5:30 PM ET ASMBPURCHASE Assembly Biosciences, Inc. View filing → $20.1M
940,499 sh × $21.37
Exec Dec 19 2024
Filed Dec 23 2024 · 5:30 PM ET XLOPURCHASE Xilio Therapeutics, Inc. View filing → $1.8M
1,759,978 sh × $1.04
Exec Dec 18 2024
Filed Dec 19 2024 · 5:30 PM ET